ATOS

$5.49

Post-MarketAs of Mar 17, 8:00 PM UTC

Atossa Therapeutics, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$5.49
Potential Upside
5%
Whystock Fair Value$5.76
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candida...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$47.28M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-48.89%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
6.30

Recent News

Simply Wall St.
Feb 9, 2026

We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Oct 22, 2025

New Strong Sell Stocks for Oct. 22

ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Sep 2, 2025

We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Jul 3, 2025

Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity

Atossa Therapeutics, Inc. (NASDAQ:ATOS) is among the best growth stocks to invest in for the next 5 years. Ascendiant Capital analysts slightly increased the price target for Atossa Therapeutics, Inc. (NASDAQ:ATOS) to $7.50, up from $7.25, with an unchanged Buy rating. This potential surge of 837% from current levels reinforces the company’s attractive valuation. In […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
May 15, 2025

Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?

Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.

BEARISH
Negative press. News cycle fixated on risk factors or misses.